Search
forLearn
5 / 801 resultslearn NMN
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn anagain
learn Ceramide AG
Research
5 / 1000+ resultsresearch The use of a retinoid receptor antagonist in a new model to study vitamin A-dependent developmental events.
The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.
research Stem cells tightly regulate dead cell clearance to maintain tissue fitness
Stem cells help remove dead cells to keep tissues healthy by balancing cell replacement and clearance.
research Angelica gigas Nakai (Korean Dang-gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy – active Phytochemicals and In Vivo Molecular Targets
Angelica gigas Nakai root extracts may help with cancer, pain, memory loss, and metabolic issues.
research Recent Progress in Prostaglandin F2αEthanolamide (Prostamide F2α) Research and Therapeutics
New research on prostamide F2α has led to treatments for glaucoma and eyelash growth and may have more medical uses.
research ACNE
Acne significantly affects mental health and quality of life, with research suggesting hormonal and genetic factors in its development and emphasizing early treatment to prevent scarring.
Community Join
5 / 1000+ resultscommunity HMI 115 hasn't done phase one yet for AGA?
User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.
community CRISPR treatment for AGA on the horizon after approval for blood disorders
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
community GT20029 Anageninc Market Availability
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Bad news about GT20029 from Anagen Inc
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.